To analyse the eect of p53 on liver tumor development, we generated transgenic mice overexpressing wild-type p53 in the liver and crossed them with transgenic mice in which the expression of the SV40 large T antigen (TAg) induces hepatic tumors. Remarkably, whereas preneoplastic TAg liver exhibited anisocaryosis and anisocytosis, TAg/p53 liver never presented any dysplastic cells. Moreover, whereas expression of p53 did not aect hepatic development, its constitutive expression in tumorigenic livers resulted in a signi®cantly enhanced apoptosis once nodules had appeared. In contrast, p53 overexpression did not modify the elevated proliferation of TAg-transformed hepatocytes and had no eect on hepatocarcinoma progression. In vitro analysis of primary hepatocytes exposed to various genotoxic agents showed that p53 failed to sensitize normal or TAgtransformed hepatocytes to apoptosis, except when high doses of doxorubicin, UV-B and UV-C radiation were used. Our results con®rmed that the hepatocyte cell type is very resistant to genotoxic agents and showed that constitutive expression of p53 failed to improve their responsiveness. In addition, our results showed that suppression of dysplastic cells, probably by restoring normal cytokinesis and karyokinesis, and enhancement of apoptosis by means of p53 overexpression were insucient to counteract or delay the TAg-induced liver tumoral progression.
To analyse the eect of p53 on liver tumor development, we generated transgenic mice overexpressing wild-type p53 in the liver and crossed them with transgenic mice in which the expression of the SV40 large T antigen (TAg) induces hepatic tumors. Remarkably, whereas preneoplastic TAg liver exhibited anisocaryosis and anisocytosis, TAg/p53 liver never presented any dysplastic cells. Moreover, whereas expression of p53 did not aect hepatic development, its constitutive expression in tumorigenic livers resulted in a signi®cantly enhanced apoptosis once nodules had appeared. In contrast, p53 overexpression did not modify the elevated proliferation of TAg-transformed hepatocytes and had no eect on hepatocarcinoma progression. In vitro analysis of primary hepatocytes exposed to various genotoxic agents showed that p53 failed to sensitize normal or TAgtransformed hepatocytes to apoptosis, except when high doses of doxorubicin, UV-B and UV-C radiation were used. Our results con®rmed that the hepatocyte cell type is very resistant to genotoxic agents and showed that constitutive expression of p53 failed to improve their responsiveness. In addition, our results showed that
Introduction
The p53 tumor suppressor gene product plays a crucial physiological role as a`cellular gatekeeper' by exerting a variety of eects following DNA damage (Lane, 1992; Levine, 1997; Levine et al., 1991) . Whereas in normal cells p53 is maintained at an undetectable or very low level, in response to genotoxic stress (such as UV, gamma irradiation and multiple chemical DNAdamaging agents including anticancer drugs, Kastan et al., 1991; Kuerbitz et al., 1992) , p53 protein accumulates and exerts multiple activities. Most of its activities are dependent on the ability to activate or repress transcription (Farmer et al., 1992; Ginsberg et al., 1991; Kern et al., 1991; Seto et al., 1992; . Thus, the biological consequence of p53 accumulation is transcriptional regulation of genes involved in cell cycle arrest (p21/Waf-1/Cip-1), repair (GADD45) and apoptosis (Bax, Bcl-2, CD95/Fas and DR5/KILLER). In addition, p53 is able to regulate expression of its negative regulator mdm2 as well as its own expression . All of these activities are thought to prevent replication or to preclude survival of cells with damaged DNA.
Inactivation of p53 represents an important step during carcinogenesis and might participate in all stages of cancer development (initiation, promotion and progression). Indeed, p53 gene mutations, deletions or allele loss are very common events in human tumors (Fearon and Vogelstein, 1990; Vogelstein and Kinzler, 1992) , and the cells derived from these cancers frequently display a loss of cell cycle arrest and a dramatic decrease in apoptosis following a genomic stress. The study of the contribution of p53 to cancer development has been facilitated by the establishment of transgenic animal models. Transgenic mice overexpressing a p53 mutant and nullizygous p53-de®cient mice are very prone to a wide variety of spontaneous tumors (Donehower et al., 1992; Lavigueur et al., 1989) , and exhibit a dramatic acceleration in growth of induced tumors (Ghebranious and Sell, 1998; Jones et al., 1997; Li et al., 1998; Symonds et al., 1994) .
Inactivation of p53 contributes not only to tumor progression but also to resistance of cancer cells to chemotherapy (Fan et al., 1994; Goto et al., 1998; Piovesan et al., 1998) , although certain exceptions have been described (Gudas et al., 1996) . Moreover, restoration of wt p53 in cells lacking or expressing mutated p53 can enhance apoptosis induced by DNAdamaging agents or chemotherapy (Blagosklonny and El Deiry, 1998; Fujiwara et al., 1994; Gurnani et al., 1999; Ju et al., 1998; Seth et al., 1997; Song et al., 1997) . Nevertheless, some tissues or organs, such as liver, are resistant to physical or chemical genotoxic agents. This could be related to a lack of accumulation of p53 following genotoxic treatment within the resistant organ (i.e. gamma irradiation, Bellamy et al., 1997a,b; Komarova et al., 1997; MacCallum et al., 1996; Midgley et al., 1995; and personal data) , suggesting that the upstream signals that direct induction of p53 are controlled in a tissue-speci®c manner.
The purpose of this study was to analyse the consequences of p53 overexpression for both hepatic tumor progression and sensitivity to DNA-damaging agents using transgenic models. To this end, we generated transgenic mice overexpressing p53 in liver (AT3-p53) and crossed them with SV40 large T antigen-(TAg) transgenic mice, which systematically develop hepatic tumors. A systematic study of homeostasis, proliferation and apoptosis during liver devel-opment and tumor progression was performed with single TAg and double TAg/p53 transgenic mice. Furthermore, to test whether p53 overexpression sensitizes hepatocytes to apoptotic agents, primary hepatocytes from our dierent transgenic mice were exposed to dierent DNA-damaging agents.
Results

Generation of transgenic mice overexpressing p53 in the liver
The murine wt p53 gene placed under the control of the human antithrombin III promoter/enhancer was used to generate transgenic mice overexpressing p53 in the liver. It has previously been shown that this promoter/enhancer gives transgene expression in liver (Bennoun et al., 1998; Dubois et al., 1991) and kidney (Tremp et al., 1995) . Three independent AT3-p53 lines were established (designated lines A, B and C). As shown in Figure 1a , Northern blotting con®rmed renal expression of p53 transgene in all lines. In contrast to renal expression, hepatic expression of p53 transgene was observed only in lines B and C. However, since the p53 transgene transcript expressed in line C liver was larger than the expected transgene mRNA, we decided to omit line C from our study. We focused our analysis on line B in which expression of authentic p53 transgene mRNA and p53 nuclear protein could be demonstrated (Figure 1a,b) . To generate p53 transgenic mice with higher transgene expression, we bred line B to homozygosity and analysed both heterozygous and homozygous transgenic mice.
p53 overexpression does not affect normal liver development
The transcriptional activity of transgenic p53 was veri®ed by Northern blotting analysis of target gene expression (mdm2, p21/Waf-1/Cip-1 and Bax). As shown in Figure 2 , mdm2 gene expression was detectable only in liver overexpressing p53. In comparison to mdm2, induction of p21/Waf-1/Cip-1 gene expression was less marked (6 ± 16-fold induction). Moreover, in AT3-p53 transgenic mice, the hepatic level of Bax a and b mRNAs was fourfold higher than in control mice.
We next analysed the eect of p53 on liver development. Histological study of liver from AT3-p53 transgenic mice revealed no obvious abnormalities, as shown in Figure 3a . These animals exhibited normal hepatic architecture comparable to that of nontransgenic mice. Analysis of proliferation by 5-bromo-2-deoxyuridine (BrdU) incorporation and apoptosis using the terminal deoxynucleotidyl transferasemediated dUTP nick end-labeling (TUNEL) assay revealed no signi®cant dierence in proliferation and apoptosis between the liver of control and AT3-p53 mice (Figure 3b) , at any age. The evolution of the ratio of liver weight to body weight, which re¯ects liver homeostasis, was similar in AT3-p53 and control mice (data not shown). Despite the induction of some p53 target genes, overexpression of p53 in liver did not appear to disturb liver development and homeostasis. The same histological analyses were performed on kidneys from the three AT3-p53 transgenic lines, and no obvious developmental and functional alteration was observed (data not shown).
p53 overexpression in the hepatic tumor transgenic model TAg/p53 prevents preneoplastic cellular dysplasia TAg mice, which express the SV40 wt large T antigen, systematically develop hepatocarcinoma as previously described (Dubois et al., 1991) , following a preneoplastic state distinguished by the presence of apoptotic cells and dysplastic cells with anisocaryosis and anisocytosis . These TAg mice died at 21 ± 26 weeks of age. To analyse the eect of p53 on tumorigenesis, we generated double transgenic mice TAg/p53. Since the wt large T antigen is a multifunctional protein which binds and functionally inactivates p53, we generated heterozygous (TAg/p53h) and homozygous (TAg/p53H) double transgenic mice to increase the level of unbound p53 protein. Northern blotting analysis and quanti®cation of mRNA levels showed an increased expression of p21/Waf-1/Cip-1 and mdm2 genes in TAg/p53H mice, con®rming the persistence of p53 transcriptional activity, but not in TAg/p53h mice ( Figure 4a ). In contrast to p21/Waf-1/ Cip-1 and mdm2 gene activation, little or no induction of Bax gene transcription was observed in liver of TAg/ p53H or TAg/p53h mice. This result was not unexpected since constitutive expression of Bax mRNAs was already high in the liver of single transgenic TAg mice.
A comparative histological analysis was performed weekly during the preneoplastic stage between 3 ± 8 weeks of age, and revealed a major morphological change between TAg and TAg/p53 mice. Whereas Proliferation and apoptosis in liver of 4-week-old homozygous AT3-p53 and control mice. BrdU-and TUNEL-labeled nuclei, which correspond to proliferating and apoptotic hepatocytes respectively, were revealed on paran sections as described in Materials and methods. The number of labeled nuclei was determined by randomly counting the number of positive nuclei per 100 nuclei with a minimum of 10 000 nuclei counted for each section. Results are expressed as mean+s.d. of at least two mice more than 10% of hepatocytes in TAg liver were dysplastic with anisocaryosis and anisocytosis in week 5, no preneoplastic dysplastic cells were observed in either heterozygous or homozygous TAg/p53 mice liver ( Figure 4c ). Moreover, in contrast to TAg mice, both heterozygous and homozygous double transgenic TAg/ p53 mice exhibited homogenous liver with a majority of mononucleated hepatocytes. In view of target gene expression, less p53 protein is required for suppression of dysplasia than for transcriptional activation.
p53 overexpression did not induce hepatic tumoral regression
Despite these preneoplastic histological discrepancies, development of hepatocarcinoma and evolution of liver weight were indistinguishable in TAg, TAg/p53h and TAg/p53H mice. This result, illustrated by the ratio of liver weight to body weight, is shown in Figure 4b . The ®rst tumoral nodules appeared around week 8 in TAg mice as well as in TAg/p53h and TAg/p53H mice (data not shown), con®rming that p53 overexpression had no eect on SV40-induced tumorigenesis. Finally, we did not detect any delay in the age at time of death of TAg/p53h and TAg/p53H mice in comparison with TAg mice. Analysis of hepatocytes in S phase by nuclear BrdU incorporation (proliferative index) showed that p53 had no eect on cell cycle arrest of transformed hepatocytes from both double transgenic mice (Figure 5a ). In contrast, the apoptotic index determined by TUNEL assay revealed a dierential response during preneo- plastic and tumoral stages. Before 8 weeks of age (preneoplastic stage), no signi®cant eect on the apoptotic index was observed in TAg/p53 livers. However, an increase in TUNEL-positive nuclei was observed during tumoral progression (beyond 8 weeks) which became signi®cant from 18 weeks on ( Figure 5a ). Apoptotic nuclei were scattered throughout TAg/p53 liver. We concluded that while overexpression of a transgenic active p53 does not delay hepatic tumor progression, it prevents the emergence of dysplastic cells (see above).
We next tested the eect of p53 in another model of hepatocarcinoma induced by TAg deleted in its p53-binding domain (TAgDp53 also called dl1137) (Bennoun et al., 1998) . TAgDp53 mice expressed a cytoplasmic TAg mutant that does not stabilize endogenous p53. No dysplastic cells were observed in the liver of these mice (Bennoun et al., 1998) . We generated double transgenic mice by crossing AT3-p53 with TAgDp53 mice and performed the same analyses as those carried out with TAg/p53 transgenic mice. p53 overexpression had no eect on hepatic proliferation, ) and double TAgDp53/p53 ( ) transgenic livers at the indicated ages (weeks). Proliferating and apoptotic hepatocyte indices were determined as described in Figure 3b and comprise internodular and nodular regions. All results are expressed as mean+s.d. of at least two mice at each age. L.w./b.w. represents the relative liver weight. *P50.025; **P50.01 apoptosis and homeostasis in the resulting double TAgDp53/p53 transgenic mice (Figure 5b ). These data con®rmed that the weak eect observed in the TAg/ p53 model was not due to p53 sequestration.
Response of AT3-p53 primary hepatocytes to genotoxic agents
In order to test whether p53 overexpression can enhance the cytotoxic eect of DNA-damaging agents, primary cultured hepatocytes from nontransgenic and AT3-p53 mice were either treated with several chemotherapeutic drugs such as doxorubicin (Dox) and methotrexate (MTX) which are known to induce various lesions by distinct mechanisms, or exposed to gamma irradiation. In addition, since UV radiation induces apoptosis and cell cycle arrest following p53 protein stabilization in various cellular types, we also compared the responsiveness of normal and AT3-p53 hepatocytes to UV irradiation.
Primary hepatocytes were treated with a range of Dox from 50 ng/ml to 1 mg/ml. Surprisingly, concentrations of 50 and 500 ng/ml of Dox did not induce hepatocyte apoptosis, but rather proliferation. In contrast, 1 mg/ml of Dox was able to induce apoptosis in more than 45% of normal hepatocytes. This apoptotic response was increased in p53-expressing hepatocytes, reaching a mortality of 84% after 44 h of treatment (Figure 6a ), suggesting that p53 promotes Dox-induced apoptosis in hepatocytes.
MTX failed to induce apoptosis in either control or p53-expressing hepatocytes, regardless of the dose (data not shown). On the other hand, we and others have observed that normal hepatocytes induced to proliferate are highly resistant to ionizing radiation. Indeed, no cell cycle arrest and a weak apoptotic response (no more than 5% of mortality) were observed following gamma irradiation up to 50 Gy, and overexpression of wt p53 did not improve hepatocyte responsiveness (data not shown).
Since experiments initially performed with classical low doses of UV-A, -B and -C (20 ± 50 Jm 
Response of TAg and TAg/p53 primary hepatocytes to genotoxic agents
The same analyses were performed with primary hepatocytes from TAg and TAg/p53 mice and similar results were obtained. As previously, MTX and ionizing radiation did not lead to apoptosis in TAg or TAg/p53H hepatocytes (data not shown). Dox was able to induce apoptosis in TAg hepatocytes, and such apoptosis was increased by p53 overexpression. This eect was observed even at a concentration of 500 ng/ ml but remained very slight compared with that in normal hepatocytes (27% versus 84%) (Figure 6b ). Similarly, UV-A treatment did not induce apoptosis in TAg and TAg/p53H hepatocytes. UV-B and -C induced-apoptosis was increased in TAg/p53H hepatocytes (Figure 6b ), but was less pronounced than in non-transformed hepatocytes. Our results con®rm the acquisition by tumoral cells of resistance towards apoptotic stimuli.
Discussion
The liver is a vital organ which assumes various biological functions, notably in metabolism and detoxi®cation of toxins and chemicals. Hepatocytes are therefore regularly exposed to mutagens, carcinogens and apoptotic agents, and must be one of the cell types most resistant to such assault. As an unfortunate consequence, hepatocytes are also highly resistant to any apoptotic treatment used in cancer therapy. This phenomenon may be the result of an insucient accumulation of p53 protein (personal data and Bellamy et al., 1997b; Midgley et al., 1995) . Based on this hypothesis, we have generated transgenic mice overexpressing wt p53, and we have investigated the in vivo and in vitro eects of wt p53 on hepatic tumor development and on hepatocyte responsiveness to DNA-damaging agents, using a double transgenic mice strategy.
p53 protein prevents the appearance of dysplastic cells during hepatocarcinogenesis
The most prominent eect of wt p53 overexpression in tumoral liver is the absence of dysplastic cells during the preneoplastic stage, which corroborates our previous works. We have already reported that expression of an SV40 large T antigen containing an intact p53-binding domain in murine liver led to anisokaryosis and anisocytosis (Dubois et al., 1991) , multinucleated, polyploid and aneuploid hepatocytes prior to hepatic tumor development. In contrast, murine liver expressing the TAg mutant lacking the p53-binding domain exhibited a majority of diploid mononucleated hepatocytes without dysplasia throughout tumor development (Bennoun et al., 1998) . These observations have underscored the propensity of p53 to regulate ploidy of hepatocytes following stress signals such as those leading to transformation. Under normal condition, p53 overexpression does not apparently compromise constitutive hepatocyte polyploidization (R. Gillet, personal communication). Recently, several reports have highlighted the crucial role of the p53 protein in mitotic spindle checkpoint control and in maintenance of genomic integrity (Cross et al., 1995;  and for review Albrechtsen et al., 1999; Jimenez et al., 1999) . Many cells lacking normal p53 activity progressively acquire polyploidy and aneuploidy, as well as genomic instability. On the other hand, when growing cells expressing wt p53 are exposed to spindle inhibitor drugs that bind microtubules (i.e. nocodazole or colcemid), mitotic cells with primarily a 4n DNA content accumulate. Conversely, p53-de®cient cells treated with spindle inhibitors do not arrest with a 4n content, but rather undergo multiple rounds of DNA replication (endoreplication) to become 8n or higher. In most cases, p53 spindle checkpoint control has been demonstrated arti®cially in vitro. In this report, we showed that wt p53 could restore an in vivo defect in hepatocyte cytokinesis and/or karyokinesis, which may re¯ect this newly reported p53 activity. The AT3-p53 transgenic mice that we have developed provide an attractive model to study interference of p53 with the mitotic spindle.
The mechanism by which p53 exerts its role in spindle checkpoint control remains unknown. Although Notterman et al. (1998) have recently reported that prevention of DNA endoreplication and polyploidization does not require the transcriptional activity of p53, p21/Waf-1/Cip-1 appears to be essential for maintaining normal polyploidization (Khan and Wahl, 1998; Lanni and Jacks, 1998) , probably by arresting the cell cycle both in G1 and in G2, as is necessary for p53-dependent spindle checkpoint control (Bunz et al., 1998 ). In our model, prevention of dysplasia by p53 requires less p53 protein than for p53-mediated transcriptional activation of certain target genes such as p21/Waf-1/Cip-1. However, the basal level of endogenous p21 protein is substantial in TAg mice (Figure 4a) , and perhaps sucient to sustain cell cycle arrest prior to DNA endoreplication in transformed hepatocytes. We do not exclude the possibility that p53 activates or inhibits transcription of certain factors involved in endoreplication or in spindle checkpoint more eciently than the p21/Waf-1/Cip-1 gene.
The eect of p53 on dysplastic cells is independent of apoptotic cell death, as the apoptotic index was unchanged during the preneoplastic stage. Finally, in our SV40 TAg model, the appearance and the growth of tumoral nodules were indistinguishable in TAg and TAg/p53 transgenic mice, indicating that the hypothetical defect in the cytokinesis checkpoint does not contribute to hepatocarcinogenesis. This ®nding does not support the notion that immortalization and neoplastic transformation of cells induced by TAg might be facilitated by mitotic checkpoint disruption and chromosomal aberrations. In consequence, the repair of a mitotic checkpoint defect induced by p53 mutation or de®ciency, which has been previously proposed to be a treatment for many types of cancers (Bunz et al., 1998) , is unlikely to be eective against all tumor types and in particular for hepatocarcinoma.
Hepatic p53-induced apoptosis is inefficient in delaying hepatic tumor progression
Our data showed that constitutive p53 overexpression in tumoral liver induces hepatocyte cell death by apoptosis at the time of appearance of tumoral nodules. This apoptosis aects both internodular and nodular cells in TAg/p53 double transgenic mice. Nevertheless, we did not see any reduction of tumoral hepatocyte growth. Thus, p53 expression appears insucient to overcome hepatic tumor progression in our TAg model. Several reports, concerning gene therapy using vectors expressing wt p53, have described the ability of the p53 gene product to suppress cancer cell growth both in vitro and in vivo in a variety of dierent tumor models including hepatocarcinoma (for review Nielsen and Maneval, 1998) . These bene®cial eects were attributed to proapoptotic and antiproliferative activities of p53 protein. There are several possible explanations for our divergent result. Our transgenic mice express wt TAg which binds to pRb and inhibition of pRb functions has been reported to bypass p53-dependent cell cycle arrest G1 (Demers et al., 1994; Hickman et al., 1997; Slebos et al., 1994) . Furthermore, it is well known that SV40 TAg may inhibit numerous apoptotic pathways (Conzen et al., 1997; Jung and Yuan, 1997; Rouquet et al., 1995; Tsai et al., 2000) , in addition to those dependent on p53. Since wt p53 is nevertheless able to revert SV40 transforming activity in ®broblast or mesothelioma cells (Fukasawa et al., 1991; Procopio et al., 1998) , our results may be explained by the induction of distinct p53-dependent responses according to cell type. These results raise the question of what signi®cance the loss of p53 activity may have for hepatocarcinogenesis.
p53 is unable to sensitize rodent hepatocytes to conventional doses of genotoxic drugs
Overexpression of p53 in normal primary hepatocytes increased their sensitivity to high doses of UV-B and -C radiation, and enhanced doxorubicin-induced cell death of hepatocytes when used at high doses as well. In contrast, hepatocytes overexpressing p53 remained highly resistant to gamma irradiation and methotrexate treatment. Furthermore, p53 overexpression was unable to improve the responsiveness of transformed hepatocytes to these DNA-damaging agents, even at high doses. We are currently addressing the eect of p53 on hepatocytes treated with other anticancer drugs which can exert their apoptotic activity via dierent pathways (i.e. 5-¯uorouracil, cisplatin or bleomycin). Nevertheless, taken together, our results con®rm the extreme resistance of hepatocytes to anticancer apoptotic drugs. Moreover, as we have mentioned before, our results suggest that in addition to the putative tissue-speci®city of the upstream signal(s) directing induction of p53, downstream signals controlling p53 activities might be regulated in a tissue-speci®c manner.
Effect of p53 overexpression in normal hepatocytes
Overexpression of wt murine p53 in non-tumorigenic liver does not lead to any abnormality in liver development or rate of cell renewal, despite transcriptional activation of p53 target genes. To our knowledge, only three transgenic models that overexpress wt p53 have been examined (Allemand et al., 1999; Godley et al., 1996; Nakamura et al., 1995) . Albeit dierent p53 targeting expression (testis, kidney, lens), these three wt p53 transgenic models exhibited particular phenotypes related to an alteration of cellular dierentiation which may be, in some cases, the result of the p53 apoptotic activity. In our hepatic model, cellular dierentiation and maturation are unaected despite neonatal expression of the p53 transgene (data not shown), and the liver develops normally without any sign of hepatic failure. From our and other results, it is evident that in vivo p53-dependent eects occur in a tissue-speci®c manner. It is not clear, however, why activation of p21/Waf-1/ Cip-1 gene expression does not aect hepatocyte cell cycle progression and postnatal liver development as has been observed in the TgTTRp21 transgenic model developed by Wu et al. (1996) . Several interpretations may explain the divergence in our results. First, it has been proposed that low to moderate concentrations of p21 could promote the assembly of active cyclin/cdk complexes, whereas at higher concentrations, p21 inhibits kinase activity, suggesting a concentrationdependent eect of p21/Waf-1/Cip-1 (La Baer et al., 1997) . A second hypothesis, that has never been evoked until now, is that p53 could in¯uence some antagonistic eects of p21/Waf-1/Cip-1 in the liver. We are currently addressing this possibility by cloning speci®c p53-target hepatic genes using the AT3-p53 transgenic mice. Finally, the absence of phenotype in our p53 mice may re¯ect the in¯uence of the genetic background, as has frequently been observed in many transgenic models. In the renal wt p53 transgenic model developed by Godley et al. (1996) , expression of the transgene in the FVB strain resulted in renal disease. Therefore, as AT3-p53 transgenic mice also express high p53 mRNA level in kidney, we are currently verifying this hypothesis by analysing p53-induced eects in the FVB genetic background.
Materials and methods
Generation and characterization of p53 transgenic mice
The murine wt p53 genomic sequences were fused to the 700 bp 5'¯anking region of the human antithrombin III gene (AT3). Insertion of the p53 sequences in a promotercontaining plasmid, deletion of a large part of the cDNA while retaining the ATG, and fusion to the p53 genomic sequences including introns 2 ± 9 as described in detail elsewhere (Allemand et al., 1999) . A fragment of SV40 provided a poly(A) signal for the transcript. The resulting DNA construct was microinjected into fertilized eggs derived from a mating of (C57B6xDBA2) F1 hybrids, as previously described (Dubois et al., 1991) . Three transgenic founders were detected by Southern blotting analysis of tail DNA using a p53 probe. RNA was isolated from kidney and liver of normal and transgenic mice by using the RNA B protocol, according to the manufacturer's recommendations (Quantum, France). The three AT3-p53 transgenic lines were maintained to homozygosity, were viable for 2 years and displayed no symptoms of disease.
Generation of double transgenic mice
Generation of TAg and dl1137 (TAgDp53) transgenic mice carrying genes encoding respectively, the SV40 large T antigen (TAg) and a TAg mutant lacking the p53-binding domain under the control of the human AT3 promoter has been described previously (Bennoun et al., 1998; Dubois et al., 1991) . Since the TAg transgene is localized on the Y chromosome, all TAg transgenic males systematically develop Oncogene Transgenic expression of p53 prevents tumoral dysplasia R Gillet et al hepatocarcinoma. The homozygous AT3-p53 transgenic line B was selected for breeding with either TAg male transgenic mice or homozygous TAgDp53 transgenic mice. The resulting double transgenic mice were designated TAg/p53 and TAgDp53/p53 mice.
Primary culture of hepatocytes
Hepatocytes were isolated by in situ collagenase A (Roche, Germany) perfusion as previously described (Dubois et al., 1991) . Following perfusion, the dissociated liver was minced and suspended in conditioned M199 medium (Life Technologies), containing 10 78 M insulin, 10 76 M thyroid hormone, 10 76 M dexamethasone sulfate and supplemented with 10% fetal calf serum (FCS), and ®ltered through a ®lter of 70-mm mesh. Cells were counted and plated on Primaria dishes (Becton Dickinson, USA) or gelatin-coated dishes (Iwaki, Japan) at a density of 5610 5 cells per 35-mm dish in conditioned M199 medium containing 10% FCS. After 2 h, the medium was removed and replaced by serum-free conditioned M199 medium. Hepatocytes were then cultured under a 7% CO 2 atmosphere.
Immunocytochemistry on primary culture of hepatocytes
Hepatocytes were ®xed for 5 min with 4% formol and incubated for 1 h at room temperature with the anti-p53 monoclonal antibody HR231. Secondary FITC-conjugated anti-mouse antibody was then used to detect p53 by immuno¯uorescence. A negative control was performed in parallel with the secondary antibody alone.
Northern blotting analysis
Total RNA was extracted from transgenic livers using the RNA B protocol (Quantum, France). RNA samples were electrophoresed in formaldehyde-containing agarose gel and transferred to Hybond membrane (Amersham, UK) in 106 SSC. Hybridization was performed 24 ± 48 h at 428C in 50 mM Tris pH 7.5, 1 M NaCl, 0.1% PPI, 106 Denhardt, 10% Dextran sulfate, 1% SDS and 50% formamide. DNA probes were labeled with (a-32 P) dCTP by a random priming extension method (Roche, Germany) and puri®ed on a G50 Sephadex column (Pharmacia, UK). The membrane was successively hybridized with appropriate probes and an 18S probe used as an internal control.
In situ detection of proliferation by BrdU incorporation
Transgenic mice were injected intraperitoneally with BrdU (Sigma) at 0.1 mg per g of body weight. Livers were removed 2 h later, ®xed in 4% formol and embedded in paran. Liver sections were incubated for 20 min in 1% H 2 O 2 solution (Merck, USA) and heated for 10 min in a microwave. Slides were denatured for 20 min in 1 N HCl treated with goat serum. Liver sections were then incubated with an anti-BrdU mAb (Dako) for 1 h at room temperature. The reaction was ampli®ed by using biotinylated anti-mouse antibody and avidin-peroxidase conjugates (Vector Laboratories, USA) and revealed using the DAB (Sigma). Liver sections were counterstained with hematoxylin/eosin (HE). The number of hepatocyte nuclei undergoing DNA synthesis was determined by randomly counting the number of BrdU-positive nuclei per 100 nuclei with a minimum of 10 000 nuclei counted for each section.
Detection of apoptosis by TUNEL method
Paran liver sections were treated for 5 min with 50 U/ml pepsin in 0.1 N HCl (Sigma Chemical Co, MO, USA) and incubated in a humid atmosphere for 1 h at 378C with a reaction mix containing 40 U TdT (Amersham, UK), 0.1 nmole/ml Bio-11-dUTP (Sigma) in a Na-cacodylate and cobalt chloride-containing buer. Endogenous phosphatases were inhibited by incubation with 2% levamisol for 10 min (Sigma). Apoptotic nuclei were detected by incubation with streptavidin-alkaline phosphatase for 30 min (Vector Laboratories, USA) followed by the use of the NBT/BCIP detection reagents (Life Technologies) in 0.1 M Tris pH 9.4 buer containing 100 mM NaCl and 50 mM MgCl 2 . Liver sections were counterstained with methyl green. The number of apoptotic nuclei was counted as described above.
Treatment with anticancer agents, gamma-and UV-irradiation
Primary cultures of hepatocytes were treated with doxorubicin (Sigma) at 50 ng/ml, 500 ng/ml and 1 mg/ml, or with methotrexate (Sigma) at doses of 125 ng/ml, 250 ng/ml and 500 ng/ml. After treatment with hepatocyte growth factor at approximately 5 ng/ml every 8 h for 2 days, hepatocytes were exposed to doses of gamma irradiation ranging from 5 ± 50 Gy using a 137 Cs source with a dose rate of 1.99 Gy/min. At dierent time points, cellular viability was assessed. For UV treatment, medium was removed and hepatocytes were exposed to UV-A and UV-B radiation at 3800 Jm 72 and 1300 Jm 72 respectively, and to UV-C radiation from 280 to 425 Jm
72
. Cells were then incubated in fresh medium at 378C for the indicated lengths of times. Viability of treated hepatocytes was initially determined using the trypan blue exclusion method. Trypsinization of hepatocytes frequently enhanced the number of dead cells, hence visual counts were performed concurrently to the trypan blue exclusion method. HeLa cells were used as experimental control cells for UV exposure and CEM for drug treatment.
Abbreviations SV40, Simian Virus 40; TAg, SV40 large T antigen; BrdU, bromodeoxyuridine; TUNEL, TdT-mediated dUTP-biotin nick end labeling; AT3, antithrombin III; UV, ultraviolet; wt, wild-type.
